Valneva (0OB3) Share Price & Analysis
0OB3 Stock Chart & Stats
- Day’s Range
- EUR 2.49 - EUR 2.61
- 52-Week Range
- EUR 2.03 - EUR 5.15
- Previous Close
- EUR 2.52
- Volume
- N/A
- Average Volume (3M)
- 26.80K
- Market Cap
- EUR 481.73M
- Enterprise Value
- EUR 516.36M
- Total Cash (Recent Filing)
- EUR 121.53M
- Total Debt (Recent Filing)
- EUR 210.23M
- Price to Earnings (P/E)
- ―
- Beta
- 1.46
- Next Earnings
- Nov 24, 2026 (Est.)
- EPS Estimate
- -0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Lyme Vaccine
The Lyme program offers a potentially transformative growth opportunity because it combines strong reported efficacy, a favorable safety profile, and advancing regulatory review. As the only late-stage candidate cited, successful approval could materially broaden Valneva’s portfolio and future revenue base.
Restructuring And Cost Discipline
The restructuring targets the cost base and project priorities after significant losses, creating a pathway toward better operating leverage. Lower R&D, marketing, and G&A expenses further support the potential for sustained cash-flow improvement if commercial sales remain resilient.
Established Commercial Portfolio
Existing marketed vaccines provide Valneva with an operating revenue base while pipeline programs develop. Material H1 sales and management’s expectation of positive commercial cash flow indicate that the portfolio can support the business, even amid product and market volatility.
Bears Say
Revenue Contraction
The sharp revenue decline indicates weaker demand and reduced scale across the commercial portfolio, limiting the company’s ability to absorb fixed costs. Continued contraction would make it harder for Valneva to fund development internally and achieve sustainable operating leverage.
Severe Margin And Loss Deterioration
Widening operating and EBITDA losses show that current sales are not translating efficiently into earnings. Lower gross margins, failed-batch costs, inventory revaluation, and manufacturing charges weaken earnings quality and raise the challenge of reaching self-sustaining operations.
Leverage And Persistent Cash Burn
A shrinking equity base combined with higher leverage reduces financial flexibility while recurring negative cash flow increases reliance on debt or equity funding. This can constrain investment in vaccines and heighten financing risk if losses continue over the next several quarters.
Valneva News
0OB3 FAQ
What was Valneva’s price range in the past 12 months?
What is Valneva’s market cap?
When is Valneva’s upcoming earnings report date?
How were Valneva’s earnings last quarter?
Is Valneva overvalued?
Does Valneva pay dividends?
What is Valneva’s EPS estimate?
How many shares outstanding does Valneva have?
What happened to Valneva’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Valneva?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Valneva
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Thomas Lingelbach
- Employees
- 620
- Website
- valneva.com
- Address
- 6 rue Alain Bombard, Saint-Herblain, GE, 44800, FR
Valneva (0OB3) Earnings & Revenues
0OB3 Earnings Call
Earnings Call SentimentNeutral
The call presented a mixed picture: materially weaker H1 2026 financials with significant revenue decline, margin compression and one-off manufacturing charges drove a much larger operating loss and EBITDA deterioration. At the same time, the company strengthened its cash position, implemented a restructuring expected to reduce costs and improve H2 cash flow, and highlighted high-impact pipeline developments — most notably strong clinical data and advancing regulatory progress for the Lyme vaccine (Pfizer EMA filing and potential decisions within 12 months), plus progress on IXCHIQ in Brazil and a promising Shigella program. Given the combination of near-term financial strain and clear strategic and clinical catalysts that could be transformative if successful, the overall tone is cautious but constructive.
View all GB:0OB3 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 6 | 7 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 7 | 0 | 5 |
